Raleigh, NC – October, 2023 – Helixomer Inc., a pioneering entity in the realm of drug development, is pleased to announce the receipt of a substantial grant from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program. The grant, amounting to $2 million, was allocated in the third quarter of 2023 to facilitate the preclinical progression of Helixomer's flagship products, HEX01 and HEX02. These products represent a groundbreaking intravenous anticoagulant and its companion reversal agent, both of which are currently in the preparatory stages for Phase 1 clinical trials.
At the forefront of pharmaceutical innovation, Helixomer leverages its proprietary RNA Aptamer technology to engineer novel therapeutics that promise to revolutionize the existing heparin market, valued at over $10 billion. The firm’s lead compounds are poised to address the critical and unmet need for precise anticoagulation management within hospital settings, thereby enhancing patient care and outcomes. The limitations of current anticoagulation solutions underscore the potential impact of Helixomer's offerings.
Dr. Thom LaBean, CEO of Helixomer Inc., expressed gratitude for the NIH's support, noting, "This grant marks a significant milestone in our journey towards advancing preclinical drug development. The challenges posed by the lack of precise control over anticoagulation in clinical settings are well-documented, impacting patient safety and outcomes. Our innovative approach aims to bridge this gap, offering a solution that promises enhanced efficacy and safety."
About Helixomer Inc.
Helixomer Inc. was co-founded by Drs. Thom LaBean and Abhichart Krissanaprasit, both of whom bring a wealth of expertise in biomolecular design and engineering to the table. The company's platform technology is dedicated to the design and synthesis of novel nucleic acid nanostructures, aimed at developing efficacious and safe therapeutics for areas with significant unmet medical needs. Helixomer's research and development efforts have been supported by a combination of grants from prestigious institutions such as NC State University, the NC Biotechnology Center, and the NIH, alongside loans from the NC Biotechnology Center.
For additional information, please contact:
David Harrell dharrell@helixomer.com Website: https://Helixomer.com